• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

使用远程医疗为有商业保险或医疗保险优势计划的患者进行丁丙诺啡诱导。

Use of Telemedicine for Buprenorphine Inductions in Patients With Commercial Insurance or Medicare Advantage.

机构信息

Interfaculty Initiative in Health Policy, Harvard University, Cambridge, Massachusetts.

Department of Health Care Policy, Harvard Medical School, Boston, Massachusetts.

出版信息

JAMA Netw Open. 2022 Jan 4;5(1):e2142531. doi: 10.1001/jamanetworkopen.2021.42531.

DOI:10.1001/jamanetworkopen.2021.42531
PMID:34989798
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8739765/
Abstract

This cross-sectional study examines the use of telemedicine for buprenorphine inductions among individuals with commercial insurance or Medicare Advantage during the temporary repeal of the Ryan Haight Act requirement of in-person evaluation before prescribing buprenorphine during to the COVID-19 pandemic.

摘要

这项横断面研究考察了在 COVID-19 大流行期间，Ryan Haight 法案要求在开处丁丙诺啡之前进行当面评估的临时取消期间，商业保险或 Medicare Advantage 个体使用远程医疗进行丁丙诺啡诱导的情况。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3eea/8739765/09910b450720/jamanetwopen-e2142531-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3eea/8739765/09910b450720/jamanetwopen-e2142531-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3eea/8739765/09910b450720/jamanetwopen-e2142531-g001.jpg

相似文献

1
Use of Telemedicine for Buprenorphine Inductions in Patients With Commercial Insurance or Medicare Advantage.使用远程医疗为有商业保险或医疗保险优势计划的患者进行丁丙诺啡诱导。
JAMA Netw Open. 2022 Jan 4;5(1):e2142531. doi: 10.1001/jamanetworkopen.2021.42531.
2
Treatment of Opioid Use Disorder Among Commercially Insured Patients in the Context of the COVID-19 Pandemic.在新冠疫情大流行背景下，商业保险患者中阿片类药物使用障碍的治疗。
JAMA. 2020 Dec 15;324(23):2440-2442. doi: 10.1001/jama.2020.21512.
3
Characteristics and correlates of U.S. clinicians prescribing buprenorphine for opioid use disorder treatment using expanded authorities during the COVID-19 pandemic.美国临床医生在 COVID-19 大流行期间利用扩大的授权开具丁丙诺啡治疗阿片类药物使用障碍处方的特征和相关性。
Drug Alcohol Depend. 2021 Aug 1;225:108783. doi: 10.1016/j.drugalcdep.2021.108783. Epub 2021 May 23.
4
Changes in Waivered Clinicians Prescribing Buprenorphine and Prescription Volume by Patient Limit.按患者限制开具丁丙诺啡的豁免临床医生及处方量的变化。
JAMA. 2023 May 23;329(20):1792-1794. doi: 10.1001/jama.2023.5038.
5
Assessment of Filled Buprenorphine Prescriptions for Opioid Use Disorder During the Coronavirus Disease 2019 Pandemic.评估 2019 冠状病毒病大流行期间治疗阿片类药物使用障碍的丁丙诺啡透皮贴剂处方
JAMA Intern Med. 2021 Apr 1;181(4):562-565. doi: 10.1001/jamainternmed.2020.7497.
6
Concentration of Patient Care Among Buprenorphine-Prescribing Clinicians in the US.美国美沙酮处方医生对患者的关注程度。
JAMA. 2021 Jun 1;325(21):2206-2208. doi: 10.1001/jama.2021.4469.
7
Barriers Rural Physicians Face Prescribing Buprenorphine for Opioid Use Disorder.农村医生在开具丁丙诺啡治疗阿片类药物使用障碍方面面临的障碍。
Ann Fam Med. 2017 Jul;15(4):359-362. doi: 10.1370/afm.2099.
8
Prescribing of Opioid Analgesics and Buprenorphine for Opioid Use Disorder During the COVID-19 Pandemic.COVID-19 大流行期间阿片类药物使用障碍的阿片类镇痛药和丁丙诺啡的处方
JAMA Netw Open. 2021 Apr 1;4(4):e216147. doi: 10.1001/jamanetworkopen.2021.6147.
9
Characteristics of Office-Based Buprenorphine Prescribers for Medicare Patients.基层医疗机构开处丁丙诺啡处方的医生特点。
J Am Board Fam Med. 2020 Jan-Feb;33(1):9-16. doi: 10.3122/jabfm.2020.01.190233.
10
Adoption of the 275-patient buprenorphine treatment waiver for treating opioid use disorder: A state-level longitudinal analysis.采用 275 例患者丁丙诺啡治疗豁免治疗阿片类药物使用障碍：一项州级纵向分析。
Subst Abus. 2020;41(2):259-268. doi: 10.1080/08897077.2019.1635959. Epub 2019 Jul 11.

引用本文的文献

1
Trends in Access to Medications for Opioid Use Disorder.阿片类物质使用障碍药物获取趋势。
JAMA Health Forum. 2025 Apr 4;6(4):e250393. doi: 10.1001/jamahealthforum.2025.0393.
2
Tele-Buprenorphine Initiations for Opioid Use Disorder Without In-Person Relationships.在无面对面接触情况下启动用于阿片类物质使用障碍的远程丁丙诺啡治疗
JAMA Netw Open. 2025 Mar 3;8(3):e250001. doi: 10.1001/jamanetworkopen.2025.0001.
3
Examining the use of telehealth to initiate buprenorphine for opioid use disorder treatment.研究使用远程医疗启动丁丙诺啡治疗阿片类药物使用障碍的情况。

本文引用的文献

1
Telemedicine increases access to buprenorphine initiation during the COVID-19 pandemic.远程医疗增加了 COVID-19 大流行期间丁丙诺啡起始治疗的可及性。
J Subst Abuse Treat. 2021 May;124:108272. doi: 10.1016/j.jsat.2020.108272. Epub 2021 Jan 15.
2
How Is Telemedicine Being Used In Opioid And Other Substance Use Disorder Treatment?远程医疗在阿片类药物和其他物质使用障碍治疗中的应用方式有哪些？
Health Aff (Millwood). 2018 Dec;37(12):1940-1947. doi: 10.1377/hlthaff.2018.05134.
3
Implementation of the Ryan Haight Online Pharmacy Consumer Protection Act of 2008. Interim final rule with request for comments.
Health Aff Sch. 2024 Nov 2;2(11):qxae137. doi: 10.1093/haschl/qxae137. eCollection 2024 Nov.
4
The Psychiatrist's Role in Treating Perinatal Opioid Use Disorder and Reducing Maternal Mortality.精神科医生在治疗围产期阿片类药物使用障碍及降低孕产妇死亡率方面的作用。
Focus (Am Psychiatr Publ). 2024 Jan;22(1):25-34. doi: 10.1176/appi.focus.20230018. Epub 2024 Jan 12.
5
Trends in Use of Telemedicine for Stimulant Initiation Among Children and Adults.儿童和成人中使用远程医疗启动兴奋剂的趋势。
Psychiatr Serv. 2024 Jul 1;75(7):630-637. doi: 10.1176/appi.ps.20230421. Epub 2024 Jan 19.
6
Patients' and Clinicians' Experiences with In-person, Video, and Phone Modalities for Opioid Use Disorder Treatment: A Qualitative Study.患者和临床医生在阿片类药物使用障碍治疗中对面对面、视频和电话模式的体验：一项定性研究。
J Gen Intern Med. 2024 Sep;39(12):2179-2186. doi: 10.1007/s11606-023-08586-6. Epub 2024 Jan 16.
7
Telemedicine Buprenorphine Initiation and Retention in Opioid Use Disorder Treatment for Medicaid Enrollees.远程医疗在医疗补助受种者阿片类药物使用障碍治疗中的丁丙诺啡起始和维持。
JAMA Netw Open. 2023 Oct 2;6(10):e2336914. doi: 10.1001/jamanetworkopen.2023.36914.
8
Telehealth Initiation of Buprenorphine for Opioid Use Disorder: Patient Characteristics and Outcomes.远程医疗启动丁丙诺啡治疗阿片类药物使用障碍：患者特征和结局。
J Gen Intern Med. 2024 Jan;39(1):95-102. doi: 10.1007/s11606-023-08383-1. Epub 2023 Sep 5.
9
Urine drug testing among Medicaid enrollees initiating buprenorphine treatment for opioid use disorder within 9 MODRN states.9 个 MODRN 州内接受医疗补助的参保者在开始接受丁丙诺啡治疗阿片类药物使用障碍时进行尿液药物检测。
Drug Alcohol Depend. 2023 Sep 1;250:110875. doi: 10.1016/j.drugalcdep.2023.110875. Epub 2023 Jun 24.
10
Trends in Use of Medication to Treat Opioid Use Disorder During the COVID-19 Pandemic in 10 State Medicaid Programs.COVID-19 大流行期间 10 个州医疗补助计划中治疗阿片类药物使用障碍药物的使用趋势。
JAMA Health Forum. 2023 Jun 2;4(6):e231422. doi: 10.1001/jamahealthforum.2023.1422.
《2008年瑞安·海特在线药房消费者保护法》的实施。带有征求意见的暂行最终规则。
Fed Regist. 2009 Apr 6;74(64):15595-625.